Patents Assigned to Genetech, Inc.
-
Publication number: 20220351810Abstract: The present disclosure relates to techniques for direct data connection (DDC) for universal collection of clinical trial health data. Particularly, aspects are directed to obtaining, by an application programming interface of a DDC system, health data for a subject from a site. The DDC system determines a visit status of the subject associated with the health data. The DDC system determines a form for the subject that is to be completed for capturing the health data. The DDC system maps data elements of the health data in the site specific format to data elements of the form in an electronic data capture format and establishes instructions for translating the data elements to the electronic data capture format. The DDC system translates the data elements based on the instructions and communicates information to an electronic data capture system.Type: ApplicationFiled: April 28, 2022Publication date: November 3, 2022Applicant: Genetech, Inc.Inventors: Mehek MOHAN, Abdi ODAY, John A. JONES
-
Patent number: 11407794Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.Type: GrantFiled: August 19, 2019Date of Patent: August 9, 2022Assignee: Genetech, Inc.Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao
-
Patent number: 11111291Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).Type: GrantFiled: September 17, 2019Date of Patent: September 7, 2021Assignee: Genetech, Inc.Inventors: Amin Famili, Germaine Fuh, Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal
-
Patent number: 10450379Abstract: Methods of treating joint damage in a subject eligible for treatment are provided involving administering an antagonist that binds to a B-cell surface marker, such as CD20 antibody, to the subject in an amount effective to slow progression of the joint damage as measured by radiography. Further provided are articles of manufacture useful for such methods.Type: GrantFiled: April 15, 2019Date of Patent: October 22, 2019Assignees: Genetech, Inc., F. Hoffmann-La Roche AG, Biogen Inc.Inventors: Mark Totoritis, Timothy Mark Shaw, Sunil Agarwal, David Yocum, Ariella Kelman
-
Patent number: 10421822Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.Type: GrantFiled: October 23, 2018Date of Patent: September 24, 2019Assignee: Genetech, Inc.Inventors: Robert F. Kelley, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
-
Patent number: 10239861Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.Type: GrantFiled: July 7, 2017Date of Patent: March 26, 2019Assignees: GENETECH, INC., CONSTELLATION PHARMACEUTICALS, INC.Inventors: Brian K. Albrecht, Daniel J. Burdick, Alexandre Cote, Martin Duplessis, Christopher G. Nasveschuk, Alexander M. Taylor
-
Patent number: 9815904Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.Type: GrantFiled: April 15, 2014Date of Patent: November 14, 2017Assignee: Genetech, Inc.Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
-
Patent number: 9625462Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.Type: GrantFiled: July 30, 2015Date of Patent: April 18, 2017Assignee: Genetech, Inc.Inventors: Yu-Ju G. Meng, Kyu H. Hong, Johnny Gutierrez
-
Patent number: 9598481Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.Type: GrantFiled: May 29, 2015Date of Patent: March 21, 2017Assignee: Genetech, Inc.Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swem
-
Patent number: 9409989Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide.Type: GrantFiled: December 27, 2013Date of Patent: August 9, 2016Assignee: Genetech, Inc.Inventors: W. Robert Arathoon, Paul J. Carter, Anne M. Merchant, Leonard G. Presta
-
Patent number: 9388171Abstract: Compounds having the formula I wherein R2, X and Z as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.Type: GrantFiled: August 27, 2013Date of Patent: July 12, 2016Assignees: GENETECH, INC., ARRAY BIOPHARMA INC.Inventors: Jim Blake, Huifen Chen, Mark Chicarelli, John Gaudino, Lewis Gazzard, Sam Kintz, Pete Mohr, Kirk Robarge, Jacob Schwarz, Aihe Zhou
-
Patent number: 9315471Abstract: The invention provides new processes for making and purifying salts of hydroxylated cyclopentapyrimidine compounds, which are useful as AKT inhibitors used in the treatment of diseases such as cancer, including the monohydrochloride salt of (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.Type: GrantFiled: May 17, 2013Date of Patent: April 19, 2016Assignee: GENETECH, INC.Inventors: Srinivasan Babu, Francis Gosselin, Yingqing Ran, Travis Remarchuk, Scott J. Savage, Jeffrey Stults, Herbert Yajima
-
Patent number: 9260425Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: August 10, 2012Date of Patent: February 16, 2016Assignee: Genetech, Inc.Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie H. Tsui, Xiaojing Wang, Zhaoyang Wen
-
Publication number: 20150099881Abstract: The invention provides new processes for making and purifying hydroxylated cyclopenta[d]pyrimidine compounds, which are useful for the treatment of diseases such as cancer as AKT protein kinase inhibitors, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.Type: ApplicationFiled: May 17, 2013Publication date: April 9, 2015Applicant: Genetech, Inc.Inventors: Jonathan W. Lane, Travis Remarchuk, Sagar Shakya, Keith L. Spencer, Peter J. Stengel
-
Publication number: 20150099880Abstract: The invention provides new processes for making and purifying salts of hydroxylated cyclopentapyrimidine compounds, which are useful as AKT inhibitors used in the treatment of diseases such as cancer, including the monohydrochloride salt of (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.Type: ApplicationFiled: May 17, 2013Publication date: April 9, 2015Applicant: Genetech, Inc.Inventors: Srinivasan Babu, Francis Gosselin, Yingqing Ran, Travis Remarchuk, Scott J. Savage, Jeffrey Stults, Herbert Yajima
-
Patent number: 8975260Abstract: Pyridazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: August 31, 2011Date of Patent: March 10, 2015Assignees: Genetech, Inc, Gilead Connecticut, Inc.Inventors: Kevin S. Currie, Xiaojing Wang, Wendy B. Young
-
Patent number: 8952043Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and where (i) X1 is N and X2 is S, (ii) X1 is S and X2 is N, (iii) X1 is CR7 and X2 is S, (iv) X1 is S and X2 is CR7; (v) X1 is NR8 and X2 is N, (vi) X1 is N and X2 is NR8, (vii) X1 is CR7 and X2 is O, (viii) X1 is O and X2 is CR7, (ix) X1 is CR7 and X2 is C(R7)2, (x) X1 is C(R7)2 and X2 is CR7; (xi) X1 is N and X2 is O, or (xii) X1 is O and X2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: January 23, 2014Date of Patent: February 10, 2015Assignee: Genetech, Inc.Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Richard Goldsmith, Robert Heald, Timothy Heffron, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, BinQing Wei
-
Patent number: 8900589Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.Type: GrantFiled: July 14, 2009Date of Patent: December 2, 2014Assignee: Genetech, Inc.Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
-
Patent number: 8895566Abstract: Compounds of Formula I are useful for inhibiting AKT protein kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Type: GrantFiled: November 15, 2012Date of Patent: November 25, 2014Assignees: Array Biopharma Inc., Genetech, Inc.Inventors: Anna Banka, Josef R. Bencsik, James F. Blake, Martin F. Hentemann, Nicholas C. Kallan, Jun Liang, Ian S. Mitchell, Stephen T. Schlachter, Eli M. Wallace, Rui Xu, Tony P. Tang
-
Patent number: RE48239Abstract: Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X1, X2, and X3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: October 30, 2018Date of Patent: October 6, 2020Assignee: Genetech, Inc.Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young